Search details
1.
Fixed-dose combination of pertuzumab and trastuzumab for subcutaneous injection plus chemotherapy in HER2-positive early breast cancer (FeDeriCa): a randomised, open-label, multicentre, non-inferiority, phase 3 study.
Lancet Oncol
; 22(1): 85-97, 2021 01.
Article
in English
| MEDLINE | ID: mdl-33357420
2.
FGFR1 amplification or overexpression and hormonal resistance in luminal breast cancer: rationale for a triple blockade of ER, CDK4/6, and FGFR1.
Breast Cancer Res
; 23(1): 21, 2021 02 12.
Article
in English
| MEDLINE | ID: mdl-33579347
3.
Immuno-priming durvalumab with bevacizumab in HER2-negative advanced breast cancer: a pilot clinical trial.
Breast Cancer Res
; 22(1): 124, 2020 11 11.
Article
in English
| MEDLINE | ID: mdl-33176887
4.
A systemic inflammation response index (SIRI) correlates with survival and predicts oncological outcome for mFOLFIRINOX therapy in metastatic pancreatic cancer.
Pancreatology
; 20(2): 254-264, 2020 Mar.
Article
in English
| MEDLINE | ID: mdl-31866391
5.
Epigenetic Regulation of Gfi1 in Endocrine-Related Cancers: a Role Regulating Tumor Growth.
Int J Mol Sci
; 21(13)2020 Jun 30.
Article
in English
| MEDLINE | ID: mdl-32630147
6.
Nintedanib plus letrozole in early breast cancer: a phase 0/I pharmacodynamic, pharmacokinetic, and safety clinical trial of combined FGFR1 and aromatase inhibition.
Breast Cancer Res
; 21(1): 69, 2019 05 24.
Article
in English
| MEDLINE | ID: mdl-31126332
7.
Neoadjuvant Management of Early Breast Cancer: A Clinical and Investigational Position Statement.
Oncologist
; 24(5): 603-611, 2019 05.
Article
in English
| MEDLINE | ID: mdl-30710068
8.
Predictors of unknown cancer in patients with ischemic stroke.
J Neurooncol
; 137(3): 551-557, 2018 May.
Article
in English
| MEDLINE | ID: mdl-29313183
9.
Fatty acid synthase is a metabolic marker of cell proliferation rather than malignancy in ovarian cancer and its precursor cells.
Int J Cancer
; 136(9): 2078-90, 2015 May 01.
Article
in English
| MEDLINE | ID: mdl-25302649
10.
Distribution of PD-L1, TROP2 and HER2- "lowness" in early triple-negative breast cancer: an opportunity for treatment de-escalation.
Clin Transl Oncol
; 26(5): 1273-1279, 2024 May.
Article
in English
| MEDLINE | ID: mdl-37851244
11.
Biomarkers in breast cancer 2024: an updated consensus statement by the Spanish Society of Medical Oncology and the Spanish Society of Pathology.
Clin Transl Oncol
; 2024 Jun 13.
Article
in English
| MEDLINE | ID: mdl-38869741
12.
Pain in Long-Term Cancer Survivors: Prevalence and Impact in a Cohort Composed Mostly of Breast Cancer Survivors.
Cancers (Basel)
; 16(8)2024 Apr 20.
Article
in English
| MEDLINE | ID: mdl-38672663
13.
Usefulness of the PERFORM questionnaire to measure fatigue in cancer patients with anemia: a prospective, observational study.
Support Care Cancer
; 21(11): 3039-49, 2013 Nov.
Article
in English
| MEDLINE | ID: mdl-23793142
14.
Usefulness and real-world outcomes of next generation sequencing testing in patients with cancer: an observational study on the impact of selection based on clinical judgement.
EClinicalMedicine
; 60: 102029, 2023 Jun.
Article
in English
| MEDLINE | ID: mdl-37304496
15.
Tumor P70S6K hyperactivation is inversely associated with tumor-infiltrating lymphocytes in triple-negative breast cancer.
Clin Transl Oncol
; 25(4): 1124-1131, 2023 Apr.
Article
in English
| MEDLINE | ID: mdl-36508123
16.
A cytotoxic ribonuclease reduces the expression level of P-glycoprotein in multidrug-resistant cell lines.
Invest New Drugs
; 30(3): 880-8, 2012 Jun.
Article
in English
| MEDLINE | ID: mdl-21286781
17.
The Homologous Recombination Deficiency Scar in Advanced Cancer: Agnostic Targeting of Damaged DNA Repair.
Cancers (Basel)
; 14(12)2022 Jun 15.
Article
in English
| MEDLINE | ID: mdl-35740616
18.
Peripheral Blood Mononuclear Cells Predict Therapeutic Efficacy of Immunotherapy in NSCLC.
Cancers (Basel)
; 14(12)2022 Jun 12.
Article
in English
| MEDLINE | ID: mdl-35740564
19.
Excess weight and anti-PD-1 immune checkpoint inhibitor's outcomes in non-small cell lung cancer.
Clin Transl Oncol
; 24(11): 2241-2249, 2022 Nov.
Article
in English
| MEDLINE | ID: mdl-35870091
20.
BERENICE Final Analysis: Cardiac Safety Study of Neoadjuvant Pertuzumab, Trastuzumab, and Chemotherapy Followed by Adjuvant Pertuzumab and Trastuzumab in HER2-Positive Early Breast Cancer.
Cancers (Basel)
; 14(11)2022 May 24.
Article
in English
| MEDLINE | ID: mdl-35681574